 |
|
|
| |
OPERA-1 trial (Study TMC435-C201): interim analysis of safety and antiviral activity of TMC435 in treatment-naÏve genotype-1 HCV patients
|
| |
| |
Reported by Jules Levin
EASL April 23-26 Copenhagen, Denmark
M. Manns,1 H. Reesink,2 C. Moreno,3 T. Berg,4
Y. Benhamou,5 Y. Horsmans,6 G. Dusheiko,7
R. Flisiak,8 P. Meyvisch,9 O. Lenz,9 V. Sekar,10
G. van't Klooster,9 K. Simmen,9 R. Verloes9
1Medizinische Hochschule Hannover, Germany; 2Amsterdam Medical Center, Amsterdam, The Netherlands; 3Erasme Hospital, Universite Libre de Bruxelles, Belgium; 4Charite-Universitätsmedizin Berlin, Campus Virchow-Klinikum, Germany; 5Centre Hospitalier Universitaire Pitie-Salpetriere, Paris, France; 6Saint-Luc Universite Catholique de Louvain, Belgium; 7Royal Free Hospital, London, UK; 8 Medical University of Bialystok, Poland;
9Tibotec, Mechelen, Belgium; 10Tibotec Pharmaceuticals, USA
|
| |
|
|
|
|
|
